Mar 4, 2019 • 9:15 am EST Corbus Pharmaceuticals Announces Appointment of Craig Millian as Chief Commercial Officer
Jan 30, 2019 • 7:30 am EST Corbus Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Jan 25, 2019 • 9:01 am EST Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Jan 3, 2019 • 10:01 am EST Corbus Pharmaceuticals Announces Strategic Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Lenabasum in Japan for Systemic Sclerosis and Dermatomyositis
Dec 18, 2018 • 8:46 am EST Corbus Pharmaceuticals Announces Issuance of Composition of Matter Patent Related to Lenabasum
Dec 17, 2018 • 7:00 am EST Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis
Nov 8, 2018 • 7:00 am EST Corbus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
Nov 6, 2018 • 8:00 am EST Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in November
Nov 5, 2018 • 8:00 am EST Corbus Pharmaceuticals to Announce Third Quarter 2018 Operational and Financial Results on November 8, 2018